Evinature

Clinically proven, evidence-based nutraceuticals for gut health

Health Tech & Life Sciences
Active
Seed Binyamina-Giv'at Ada Founded 2021
Total raised
$6.5M
Last: Seed 2024-02
Stage
Seed
Founded
2021
Headcount
17
HQ
Binyamina-Giv'at Ada
Sector
Health Tech & Life Sciences

About

Evinature was created at the intersection of two complementary wellness philosophies. By bringing together modern science and traditional botanical knowledge, we offer natural, well-researched solutions that are embraced by health-minded communities worldwide.

We believe it’s time for wellness to prioritize global accessibility—giving consumers clear assessments, transparent information, and thoughtfully formulated products. No trends, no hype, no confusion. We focus on developing, evaluating, and refining our formulas responsibly, then sharing what we learn with the community.

Tailored Support

Every body is unique. That’s why our evidence-informed protocols are designed to support each individual’s needs and personal wellness goals. After completing our assessment, consumers receive personalized guidance based on their overall profile.

Guided Care

Ongoing digital check-ins help ensure your protocol continues to support your evolving needs. To make the journey even smoother, we also provide optional clinic-based guidance for consumers who prefer additional support from wellness professionals.

Research & Development

Our team continually advances our formulas through ongoing research and collaborations with leading medical centers across the U.S. This work enables us to responsibly develop nutraceuticals that are accessible to consumers worldwide.

Commitment to Evidence

At Evinature, evidence comes before trends. With a foundation in clinical research and scientific integrity, we focus on quality, transparency, and education—sharing insights that consumers can trust and understand.

Community-Driven Insight

Consumers are an essential source of real-world learning. By completing the assessment, every individual contributes valuable insights that help us expand our research and share meaningful information with the broader community. Together, we continue to build a resource grounded in lived experience and ongoing discovery.

Funding history · 3 rounds · $6.5M total

2024-02
Seed $2.5M
2023-10
Seed $2.0M
2022-06
Pre-Seed $2.0M

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Evinature's primary focus in the health tech sector?
Evinature specializes in clinically proven, evidence-based nutraceuticals for gut health, particularly focusing on conditions like IBD, Crohn's, and Colitis.
When was Evinature founded and what is its current employee count?
Evinature was founded in April 2021 and currently has 17 employees.
What is the total funding Evinature has raised to date?
Evinature has raised a total of $6,500,000 USD across multiple funding rounds. For a full financing history, please refer to startupim.
Which investor participated in Evinature's Pre-Seed round in June 2022?
In June 2022, Ratio Technologies invested in Evinature's Pre-Seed round, which raised $2,000,000 USD.
What was Evinature's most recent funding round?
Evinature's most recent funding round was a Seed round in February 2024, raising $2,500,000 USD.
What is the significance of Evinature's CurQD Protocol?
The CurQD Protocol is Evinature's flagship nutraceutical strategy for IBD, with different protocols tailored to individual patient needs. Recent news in May 2025 highlighted new CurQD research at the USA's largest GI Conference.
Has Evinature expanded its reach within the US medical system?
Yes, in April 2024, Evinature announced its integration across 35 US medical centers to streamline IBD treatment accessibility.
What was a notable partnership for Evinature in August 2023?
In August 2023, Evinature signed an exclusive distribution deal with multinational company Adacyte Therapeutics to expand IBD treatment accessibility.
What is Evinature's product DivertX designed for?
Evinature's product DivertX is formulated for diverticulitis and IBS, with a press release in January 2024 describing it as a revolutionary natural approach to Post-Diverticulitis Syndrome.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsHerbals
Target customers
Healthcare & Life SciencesHealthcarePatients
Business model
B2BB2B2CB2C

Highlights

1 PatentsVerified

Tags

supplementsmedical-productsmental-healthpharmaceuticalsgastroenterologytreatmentsinflammatory-diseasescrohn-s-diseasenutraceuticals